Efthymia Papalexi
Overview
Explore the profile of Efthymia Papalexi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
19649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kleppe M, Koche R, Zou L, van Galen P, Hill C, Dong L, et al.
Cancer Cell
. 2018 Apr;
33(4):785-787.
PMID: 29634952
No abstract available.
12.
Butler A, Hoffman P, Smibert P, Papalexi E, Satija R
Nat Biotechnol
. 2018 Apr;
36(5):411-420.
PMID: 29608179
Computational single-cell RNA-seq (scRNA-seq) methods have been successfully applied to experiments representing a single condition, technology, or species to discover and define cellular phenotypes. However, identifying subpopulations of cells that...
13.
Zheng S, Papalexi E, Butler A, Stephenson W, Satija R
Mol Syst Biol
. 2018 Mar;
14(3):e8041.
PMID: 29545397
Hematopoietic stem cells (HSCs) give rise to diverse cell types in the blood system, yet our molecular understanding of the early trajectories that generate this enormous diversity in humans remains...
14.
Kleppe M, Spitzer M, Li S, Hill C, Dong L, Papalexi E, et al.
Cell Stem Cell
. 2018 Feb;
22(2):277.
PMID: 29395057
No abstract available.
15.
McKenney A, Lau A, Hanasoge Somasundara A, Spitzer B, Intlekofer A, Ahn J, et al.
J Clin Invest
. 2018 Jan;
128(2):789-804.
PMID: 29355841
Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are...
16.
Kleppe M, Koche R, Zou L, van Galen P, Hill C, Dong L, et al.
Cancer Cell
. 2017 Dec;
33(1):29-43.e7.
PMID: 29249691
Genetic and functional studies underscore the central role of JAK/STAT signaling in myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate transformation in MPNs are not fully delineated, and clinically utilized...
17.
Kleppe M, Spitzer M, Li S, Hill C, Dong L, Papalexi E, et al.
Cell Stem Cell
. 2017 Oct;
21(4):489-501.e7.
PMID: 28965767
JAK1 is a critical effector of pro-inflammatory cytokine signaling and plays important roles in immune function, while abnormal JAK1 activity has been linked to immunological and neoplastic diseases. Specific functions...
18.
Papalexi E, Satija R
Nat Rev Immunol
. 2017 Aug;
18(1):35-45.
PMID: 28787399
Advances in single-cell RNA sequencing (scRNA-seq) have allowed for comprehensive analysis of the immune system. In this Review, we briefly describe the available scRNA-seq technologies together with their corresponding strengths...
19.
LaFave L, Beguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al.
Nat Med
. 2016 Jun;
22(6):578-9.
PMID: 27270773
No abstract available.
20.
Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Martin M, et al.
Blood
. 2015 Oct;
126(22):2479-83.
PMID: 26443624
The development of the dual Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib for the treatment of myeloproliferative neoplasms (MPNs) has led to studies of ruxolitinib in other clinical contexts, including JAK-mutated...